1
عمومی::
کلوپیدوگرل
Polymorphisms in CYP2C19 result in variable drug response to clopidogrel and several antidepressants.
The CYP2C19 PM phenotype results in a lack of efficacy for the antiplatelet prodrug clopidogrel.
For activation, clopidogrel requires a two-step metabolism by several different CYP450 with CYP2C19 being a significant contributor.
Studies have demonstrated, and the FDA has added to the label, that deficiencies in CYP2C19 activity may result in the increased risk of adverse cardiovascular outcomes because the PM does not activate clopidogrel sufficiently (Scott et al, 2011).
metabolism of clopidogrel to the active metabolite (Sibbing et al, 2010).
واژگان شبکه مترجمین ایران